Volume 12, Number 10—October 2006
Research
Health Benefits, Risks, and Cost-Effectiveness of Influenza Vaccination of Children
Lisa A. Prosser*†
, Carolyn Buxton Bridges‡, Timothy M. Uyeki‡, Virginia L. Hinrichsen*†, Martin I. Meltzer‡, Noelle-Angelique M. Molinari‡, Benjamin Schwartz‡, William W. Thompson‡, Keiji Fukuda‡, and Tracy A. Lieu*†§
, Carolyn Buxton Bridges‡, Timothy M. Uyeki‡, Virginia L. Hinrichsen*†, Martin I. Meltzer‡, Noelle-Angelique M. Molinari‡, Benjamin Schwartz‡, William W. Thompson‡, Keiji Fukuda‡, and Tracy A. Lieu*†§Table 5
Incremental cost-effectiveness ratios for use of inactivated and live attenuated influenza vaccination in varying age and risk groups compared to no vaccination, mean (2.5% and 97.5% bootstrapped percentiles)*
| Age group | Using inactivated influenza vaccine | Using live, attenuated influenza vaccine† | ||
|---|---|---|---|---|
| Children not at high risk | Children at high risk | Children not at high risk | ||
| $ per influenza episode averted‡ | ||||
| 6–23 mo | 340 (CS–4,690) | CS (CS–4,090) | 240 (CS–3,890) | |
| 2 y | 400 (CS–3,990) | CS (CS–3,620) | 330 (CS–3,340) | |
| 3–4 y | 440 (10–3,590) | 20 (CS–3,410) | 440 (CS–3,170) | |
| 5–11 y | 800 (180–5,850) | 210 (CS–5,560) | 720 (170–5,290) | |
| 12–17 y | 1,070 (250–7,780) | 310 (CS–7,360) | 980 (240–7,070) | |
| $ per hospitalization averted‡ | ||||
| 6-23 mo | 19,000 (CS–350,000) | CS (CS–132,000) | 14,000 (CS–287,000) | |
| 2 y | 37,000 (CS–633,000) | CS (CS–232,000) | 30,000 (CS–522,000) | |
| 3–4 y | 84,000 (1,000–2,587,000) | 1,000 (CS–750,000) | 74,000 (CS–2,227,000) | |
| 5–11 y | 202,000 (38,000–1,929,000) | 9,000 (CS–310,000) | 184,000 (35,000–1,629,000) | |
| 12–17 y | 206,000 (43,000–1,768,000) | 10,000 (CS–304,000) | 188,000 (40,000–1,575,000) | |
| $ per death averted‡ | ||||
| 6–23 mo | 22 m (CS–1,109 m) | CS (CS–342 m) | 16 m (CS–880 m) | |
| 2 y | 42 m (CS–1,762 m) | CS (CS–591 m) | 34 m (CS–1,435 m) | |
| 3–4 y | 98 m (1 m–6,840 m) | 1 m (CS–1,873 m) | 86 m (CS;5,991 m) | |
| 5–11 y | 234 m (32 m–5,993 m) | 10 m (CS–876 m) | 212 m (32 m–5,331 m) | |
| 12–17 y | 238 m (37 m–5,607 m) | 12 m (CS–892 m) | 217 m (34 m–5,007 m) | |
| $ per quality-adjusted life-year saved | ||||
| 6–23 mo | 12,000 (CS–208,000) | CS (CS–85,000) | 9,000 (CS–167,000) | |
| 2 y | 18,000 (CS–217,000) | CS (CS–100,000) | 15,000 (CS–180,000) | |
| 3–4 y | 28,000 (1,000–290,000) | 1,000 (CS–130,000) | 25,000 (CS–236,000) | |
| 5–11 y | 79,000 (15,000–682,000) | 7,000 (CS–260,000) | 72,000 (14,000–592,000) | |
| 12–17 y | 119,000 (24,000–1,040,000) | 10,000 (CS–367,000) | 109,000 (22,000–888,000)
*CS, cost savings; m, million. | |
*CS, cost savings; m, million.
†Numerator does not include productivity losses.
‡Italics indicate that live, attenuated influenza vaccine is not licensed for children <5 y.
